PIPELINE
Cell Type Matters
VIEW OUR PROGRAMS
CAR-T
CAR-T therapy is a form of anti-cancer therapy in which T cells are genetically modified to attack tumors, an approach that has revolutionized how cancer is treated. Currently, all commercially available CAR-T therapies are autologous, where the T cells are derived from each patient. Poseida believes that the future of CAR-T and our ability to offer new treatment options lies in allogeneic approaches, where the T cells are derived from healthy donors.
Our clinical and preclinical candidates are designed as off-the-shelf treatments for cancer. We modify healthy donor derived T cells using Cas-CLOVER gene editing to disrupt expression of T cell receptor beta and human leukocyte antigens (HLA). Specifically, T cell receptor beta gene deletion eliminates or reduces unwanted immune reactions, such as graft-versus-host-disease (GvHD). Partial beta-2 microglobulin knock out improves persistence by eliminating CAR-T rejection by the patient’s immune system via mismatched HLA proteins. The large cargo capacity of our transposon-based DNA delivery system allows us to develop allogeneic CAR-Ts able to target multiple antigens for greater tumor recognition capacity.
INDICATIONS
PRECLINICAL
IND-ENABLING
PHASE 1
PHASE 2
Heme Malignancies and Autoimmune Diseases
P-BCMA-ALLO1 Multiple myeloma
PHASE 1
This allogeneic CAR-T candidate targeting B cell maturation antigen, or BCMA, is in development to treat relapsed/refractory multiple myeloma. This allogeneic program offers an improved VH-based binder which targets BCMA. This program is being developed in partnership with Roche and has shown early evidence of encouraging safety and efficacy.
P-CD19CD20-ALLO1 B-cell malignancies
PHASE 1
This allogeneic dual CAR-T candidate targets both CD19 and CD20 antigens to treat B-cell malignancies. Dual targets address the limitations of single antigen loss and tumor variability. This program is being developed in partnership with Roche.
P-BCMACD19-ALLO1 Multiple myeloma and autoimmune diseases
IND-ENABLING
This fully allogeneic CAR-T product candidate expresses two full-length CARs targeting BCMA and CD19, each with an optimized intracellular domain (ICD) for enhanced potency, to treat relapsed/refractory multiple myeloma and autoimmune diseases.
P-CD70-ALLO1 Acute myeloid leukemia
Option
Option
IND-ENABLING
This allogeneic CAR-T candidate targets CD70 for the treatment of acute myeloid leukemia.
Novel Dual CAR Heme malignancies, including multiple myeloma
PRECLINICAL
Targets not yet disclosed.
Solid Tumor*
P-MUC1C-ALLO1 Breast, ovarian, colorectal, lung, pancreatic, renal
PHASE 1
This allogeneic CAR-T candidate is in development for multiple solid tumor indications including breast, colorectal, lung, ovarian, pancreatic and renal carcinomas, as well as other cancers expressing a cancer-specific form of the Mucin 1 protein called MUC1-C.
P-PSMA-ALLO1 Prostate cancer
PRECLINICAL
This allogeneic CAR-T candidate targets prostate-specific membrane antigen, or PSMA, to treat prostate cancer. This allogeneic program offers improved VH-based binding technology targeting PSMA, which can potentially enhance anti-tumor efficacy.
ConvertibleCAR® x2 Solid tumor programs
PRECLINICAL
Targets not yet disclosed.
*Solid tumor targets identified in conjunction with the research collaboration and license agreement with Astellas yet to be disclosed
Genetic Medicines
Our system of proprietary, non-viral tools including transposon-based DNA delivery, Cas-CLOVER™ site-specific gene editing, and lipid nanoparticle delivery technology can be used individually or together – with the capacity to treat rare genetic diseases as well as address much more prevalent diseases.
INDICATION
PRECLINICAL
IND-ENABLING
PHASE 1
PHASE 2
Liver Directed
P-KLKB1-101 Hereditary Angioedema (HAE)
PRECLINICAL
This is an investigational liver-directed non-viral gene editing approach designed to enable high fidelity editing at the pre-kallikrein gene, or KLKB1, for targeted correction of hereditary angioedema, or HAE. It utilizes the Cas-CLOVER nuclease, which is engineered for high specificity, to achieve site-specific gene editing. HAE is a rare, inherited disorder that results in the swelling of the limbs, intestinal tract, and airways, which can be both debilitating and life-threatening. Preclinical data demonstrate therapeutically relevant reduction of pre-kallikrein levels in mouse and non-human primate models.
P-FVIII-101 Hemophilia A
PRECLINICAL
This is an investigational liver-directed gene insertion program combining our transposon-based DNA delivery system with our non-viral nanoparticle technology for the in vivo treatment of Hemophilia A. Hemophilia A is a hereditary disorder caused by a deficiency in Factor VIII, or FVIII, production resulting in excessive bleeding occurring either spontaneously or due to trauma. Our preclinical data demonstrate the potential to correct FVIII deficiency to near-normal levels in both juvenile and adult mouse models using our fully non-viral, whole gene insertion system.
*Solid tumor targets identified in conjunction with the research collaboration and license agreement with Astellas yet to be disclosed
Our Partnerships
Poseida welcomes partners and collaborators to help us translate our proprietary non-viral genetic editing platforms into cell therapies and genetic medicines with the capacity to cure. The numerous opportunities we look forward to cannot be addressed by one organization alone. Therefore, we strive to partner with industry leaders that share our commitment to develop transformative treatments for those with limited or no therapeutic options.
With Roche, our strategic collaboration focuses on allogeneic CAR-T therapies directed at blood cancers. This partnership includes multiple existing Poseida investigational programs as well as future development programs for novel off-the-shelf cell therapies against targets in multiple myeloma, B-cell lymphoma and other blood cancers.
With Astellas, our research collaboration and license agreement combines Poseida’s proprietary allogeneic CAR-T platform with an Astellas subsidiary’s (Xyphos) ACCEL™ technology to create investigational treatments that target solid tumors beyond those in our pipeline. This latest collaboration expands the strategic relationship that began between the two companies in 2023.
Partner With Us
If you are interested in collaborating with Poseida to usher in a new class of innovative cell therapies and genetic medicines, please contact us. We are actively seeking collaborators in these areas:
- Allogeneic CAR-T or TCR-T therapies to treat solid tumors
- In vivo liver or other tissue-directed genetic medicines
- Application of our technology in therapeutic areas beyond oncology and rare genetic diseases
- Application of our genetic engineering tools and supporting technologies in other areas beyond Poseida’s core pipeline focus
